Recently, researchers analyzed mutational signatures of RAS/BRAF/EGFR wild-type mCRC patients pooled from three large, randomized trials who were treated with EGFR inhibition and chemotherapy in the first-line setting and EGFR inhibition alone in the third-line setting, and also analyzed transcriptional changes in a CRC cell line resistant to chemotherapy plus cetuximab. The gene discussed is EGFR; the disease is colorectal carcinoma.